Aktis Oncology, Inc. (AKTS) stock
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)
Close on Nov 17, 2026Market cap $907.15MP/E –Yield –
Aktis Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$33.81M | – |
| Q2 FY2026 | Jun 30, 2026 | -$28.02M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.05M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.66M | – |
See a number that looks wrong?